How NOW on Breast Implants? - Steven Milloy - MensNewsDaily.com™
MND
COMMENTARY
How NOW on Breast Implants?
July 28,
2003
by Steven Milloy
The National Organization for Women portrays itself
as being in favor of women making their own informed choices for their
bodies. So it’s curious that NOW opposes women choosing to have silicone
breast implants .
NOW released a report this week intended to scare women away from implants
as manufacturers apply to the Food and Drug Administration for approval
of SBIs. NOW essentially claims that not enough data exist about the
safety of SBIs.
That claim ignores the conclusions of a 1999 report by a group of multidisciplinary
scientific and medical experts assembled by the National Academy
of Sciences’ Institute of Medicine .
The IOM panel reviewed the existing scientific literature on SBIs --
well over 1,000 published studies -- and concluded that the weight of
evidence does not support an association between SBIs and autoimmune
disease , dysfunction of the immune system, connective tissue/rheumatic
disease , cancer, neurological disease or adverse effects on breastfeeding
infants, though local complications may occur in some women.
One reason there have been so many studies on SBIs is that they have
been around since the 1970s.
It’s awfully silly of NOW to claim that 30 years of real-world
data captured in more than 1,000 studies is an insufficient basis to
draw conclusions about SBI safety. But what can an activist group do
when the science just won’t cooperate?
NOW’s decade-old crusade against SBIs was renewed in May when
it held a “Symposium on the Safety and Effectiveness of Silicone
Gel-Filled Breast Implants.” The symposium apparently was timed
to coincide with the release of a report
to Congress from the National Institutes of Health on SBI safety.
I suspect that NOW hoped the NIH report would raise concerns about
the safety of SBIs and scheduled the symposium in hopes of exploiting
any bad news.
The symposium featured prominent anti-implant activist Diana
Zuckerman and Lori Brown , an anti-implant activist
who works at the FDA.
Brown’s presence alongside that of several other federal employees
featured at the symposium seemed intended to give the impression that
the federal government endorsed NOW’s views.
It was all for naught, however.
The NIH report, which incorporated recent long-term (10-year) assessments
of women with implants, reconfirmed the IOM’s conclusions on connective
tissue disease and even found a slight decrease in breast cancer incidence.
Compared with other plastic surgery patients, women with SBIs reportedly
had lower rates for nearly every other cancer and, consistent with previous
findings concerning people who undergo elective surgery, had lower mortality
rates than their peers.
So why is NOW -- the supposed champion of women rather than the
government making their own choices -- now working to have the
government deny women that very right?
Could the explanation be NOW’s narrow view of what is right for
women and their bodies? Could the answer lie in an alliance between
NOW and other activist groups that are fueled by trial lawyers? Is there
a more direct relationship with trial lawyers?
NOW, after all, was asked by personal injury lawyers in the mid-1990s
to get involved in the SBI litigation.
Questions abound as NOW partnered at the symposium with the personal
injury lawyer-friendly Public Citizen and the printed
materials available at NOW’s press conference this week included
a brochure from the Command Trust Network , the alpha group
of anti-breast implant activists and historic recruiting tool for breast
implant plaintiffs.
Unfortunately, the controversy over SBIs is unlikely to subside. Women
should expect continued fear-mongering by personal injury lawyer-inspired
activists.
It has been four years since the IOM report, an unbiased consensus
report from qualified experts. An update of that report, broader and
more comprehensive than the recent NIH report, would inform the public
of recent SBI-related research. More than 250 scientific studies and
articles on SBIs have been published since 1999.
Such an update would also assist the FDA in the SBI approval process,
which is growing more political by the day.
NOW is a good reason -- as well as a good time -- to get the IOM update
process rolling.